Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trio of antibodies may enable earlier diagnosis of axSpA

Publish date:: July 20, 2020

Key clinical point: A panel of three antibodies to novel axial spondyloarthritis peptides may enable earlier diagnosis of the disease.

Major finding: Panel antibodies were detected in 14.2% of patients with early axial spondyloarthritis, compared with just 5.3% of patients with nonspecific chronic low back pain (P = .0484), for a positive likelihood ratio of 2.7.

Study details: A cross-sectional study with a mixed cohort (76 patients with early axial spondyloarthritis, 75 with nonspecific chronic low back pain, 60 with RA, and 94 healthy controls) and an axial spondyloarthritis cohort (174 patients, 79 of whom had early disease).

Disclosures: Dr. Somers and three coauthors disclosed having a patent pending on the markers. The study was funded by a personal grant from the Agency for Innovation by Science and Technology Flanders.

Citation:

Quaden D et al. Arthritis Rheumatol. 2020 Jul 8. doi: 10.1002/art.41427.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Ankylosing spondylitis

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,

Novel study explores link between primary immunodeficiencies, rheumatic diseases,

Lower TNF inhibitor efficacy observed in women with nonradiographic axSpA,

Shingrix effective in older adults with preexisting immune-mediated disorders,

Trabecular bone loss may contribute to axial spondyloarthritis progression,